Abstract:The tumor suppressor p53 plays a key role in the regulation of cell cycle, apoptosis, DNA repair, and senescence. It acts as a transcriptional factor, and is able to activate various genes to exert specific functions. MDM2, the main regulator of p53, inhibits the function of p53 through direct interaction. On the basis of this finding, inhibiting the MDM2-p53 interaction can be a potentially important target for cancer therapy. We showed here that L2, an analog of small-molecule MDM2 antagonist nutlins, stabilized p53 and selectively activated the p53 pathway in p53 wild-type A549 cells, resulting in a pronounced antiproliferation effect through inducing cell cycle arrest and apoptosis. Meanwhile, we confirmed by immunoprecipitation analysis that L2 could also inhibit MDM2-p53 interaction, similar to nutlin-1. Real-time PCR results revealed that L2 had no effect on the p53 gene transcriptional level, but it could induce the upregulation of p21 at the transcriptional level, which was the downstream of p53. Therefore, we concluded that the accumulation of p53 caused by L2 was mainly because of the decrease of the protein degradation rather than the elevation of p53 gene expression. Furthermore, no phosphor-p53 formed after L2 treatments, indicating that a genetoxic mechanism was unlikely to contribute to the activation of p53 by L2. In conclusion, the data acquired from A549 cells indicated that L2 exhibited high anti proliferation activity by disrupting MDM2-p53 interaction, and that the mechanism was derived from the activation of p53 and the p53 pathway. It was also surprising that L2 showed high anti proliferation effect against p53 null H L60 cells, which was quite different from nutlin-1. G(2)/M phase arrest might have contributed to the high anti proliferation activity of L2 on HL60 cells. The changes of p53 and MDM2 protein levels in L2-treated HL60 cells indicated that the mechanisms involved in the cell cycle arrest in A549 and HL60 cells were probably different, to which our future research would be devoted. Anti-Cancer Drugs 20:416-424 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Identification of a small molecule 1,4-bis-[4-(3-phenoxy-propoxy)-but-2-ynyl]-piperazine as a novel inhibitor of the transcription factor p53

Small Molecule Inhibitors of the P53-Mdm2

Pharmacological Activation of the P53 Pathway by a New Compound CYZ2017 Exerts Anti-Tumor Effects

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Recent Advances of P53-Mdm2 Small Molecule Inhibitors (2011-Present).

A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth

Activating p53 with a Mutant-Specific Small Molecule

Ginkgo Biflavones Cause p53 Wild-Type Dependent Cell Death in a Transcription-Independent Manner of p53

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

A Small Molecule That Disrupts Mdm2-p53 Binding Activates P53, Induces Apoptosis, and Sensitizes Lung Cancer Cells to Chemotherapy

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the Mdm2-P53 Interaction

Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity